title: NICE guidance on dasatinib, high-dose imatinib, and  nilotinib for patients with CML who are resistant or  intolerant to imatinib.
authors.forename: Scott
authors.initials: S
authors.lastname: Goulden
authors.forename: Frances
authors.initials: F
authors.lastname: Sutcliffe
authors.forename: Andrew
authors.initials: A
authors.lastname: Stevens
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001549:Benzamides; D002986:Clinical Trials as Topic; D000069439:Dasatinib; D003695:Delivery of Health Care / Q000458:organization & administration; D019008:Drug Resistance, Neoplasm; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy*; D010879:Piperazines / Q000008:administration & dosage* / Q000009:adverse effects; D017410:Practice Guidelines as Topic; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage*; D011743:Pyrimidines / Q000008:administration & dosage* / Q000009:adverse effects; D013844:Thiazoles / Q000008:administration & dosage*; D006113:United Kingdom
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D013844:Thiazoles; D000068877:Imatinib Mesylate; C498826:nilotinib; D000069439:Dasatinib